(Q28267204)

Blood transfusion in adult Jehovah's Witnesses. A case study of one congregation

20 April 2017

1 reference

The human plasma proteome: a nonredundant list developed by combination of four separate sources

20 April 2017

1 reference

Faith, identity, and leukemia: when blood products are not an option

20 April 2017

1 reference

Palifermin for oral mucositis after intensive therapy for hematologic cancers

20 April 2017

1 reference

The use of desmopressin as a hemostatic agent: a concise review

20 April 2017

1 reference

Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion.

20 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Impact of a transfusion-free program on non-Jehovah's Witness patients undergoing liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Why some Jehovah's Witnesses accept blood and conscientiously reject official Watchtower Society blood policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Responses by pregnant Jehovah's Witnesses on health care proxies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Haematological care of the Jehovah's Witness patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Erythropoietin permits high-dose chemotherapy with peripheral blood stem-cell transplant for a Jehovah's Witness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Clinical and ethical issues in the treatment of a Jehovah's Witness with acute myeloblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Autologous stem-cell transplantation can be performed safely without the use of blood-product support.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

The use of blood conservation methods in addition to erythropoietin allows myeloablative allogeneic stem cell transplantation without the use of blood products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Transfusion-free reduced-intensity conditioned allogeneic stem cell transplantation in a Jehovah's witness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Platelet transfusion requirements during autologous peripheral blood progenitor cell transplantation correlate with the pretransplant platelet count

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Acute severe isovolemic anemia impairs cognitive function and memory in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Oxygen reverses deficits of cognitive function and memory and increased heart rate induced by acute severe isovolemic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Electrocardiographic ST-segment changes during acute, severe isovolemic hemodilution in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Severity of anaemia and operative mortality and morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Mild hypothermia has minimal effects on the tolerance to severe progressive normovolemic anemia in Swine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Hyperbaric oxygen therapy in the management of severe acute anaemia in a Jehovah's witness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Severe autoimmune hemolytic anemia treated by paralysis, induced hypothermia, and splenic embolization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

RBC transfusion requirements after allogeneic marrow transplantation: impact of the before-transplant Hb level on transfusion and early survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Erythropoietin in stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

rHuEpo before high-dose therapy allows autologous peripheral stem-cell transplantation without red blood cell transfusion: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Phlebotomy for diagnostic laboratory tests in adults. Pattern of use and effect on transfusion requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

The use of recombinant factor VIIa in the treatment of bleeding disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Experiences with recombinant human factor VIIa in patients with thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Dosing with recombinant factor viia based on current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

Substitutes and alternatives to platelet transfusions in thrombocytopenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

High-dose chemotherapy and autologous peripheral blood stem cell transplantation in lymphoma without blood product support

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

7 January 2021

Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

7 January 2021

Failure to achieve a threshold dose of CD34+ CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

7 January 2021

Variables associated with the platelet count 6 weeks after autologous peripheral blood progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

7 January 2021

Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

7 January 2021

New thrombopoietic growth factors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

7 January 2021

Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

7 January 2021

Erythropoietin, the FDA, and oncology

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

7 January 2021

Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

7 January 2021

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

7 January 2021

Reducing adult phlebotomy blood loss with the use of pediatric-sized blood collection tubes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

7 January 2021

Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.5

7 January 2021